Global Lung Cancer Diagnostics Market Size study & Forecast, by Cancer Type (Small Cell Lung Cancer, Non-small Cell Lung Cancer), by Test (Imaging Test, Biopsy, Sputum Cytology, Molecular Testing), by End User (Hospitals, Specialty Clinics, Others) and R

Global Lung Cancer Diagnostics Market Size study & Forecast, by Cancer Type (Small Cell Lung Cancer, Non-small Cell Lung Cancer), by Test (Imaging Test, Biopsy, Sputum Cytology, Molecular Testing), by End User (Hospitals, Specialty Clinics, Others) and Regional Analysis, 2023-2030

Global Lung Cancer Diagnostics Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than X% over the forecast period 2023-2030. Lung cancer occurs when cells grow uncontrollably, resulting in the formation of masses called tumors. It can start in any area of the lung, but most cases originate from the cells lining the airways, such as the bronchi and bronchioles. Therefore, lung cancer is often referred to as bronchogenic cancer or bronchogenic carcinoma. The market for lung cancer diagnostics is expanding due to advanced technologies that increase early detection of the disease. However, market growth is challenged by high testing costs and strict regulations for cancer diagnostic products.

The market is propelling due to the rise in prevalence of lung cancer. According to a report published by cancer.net, the prevalence of lung cancer is on the rise, making it the second most common cancer in both men and women in the U.S. In 2021, there were an estimated 228,820 new cases and 135,720 deaths from the disease. The five-year survival rate for lung cancer is only 18%, which is lower than other types of cancer. It is predicted that 127,070 deaths from lung cancer would occur in the United States in 2023, and globally, an estimated 1,796,144 deaths were attributed to the disease in 2020. The development of new and innovative diagnostic technologies, such as non-invasive methods such as CT scans and PET scans, has improved the accuracy and efficiency of early lung cancer detection. Additionally, government initiatives towards diagnosis and detection of cancer are creating more opportunities for the market to grow. However, a lack of skilled and well-trained professionals hinder market growth during the forecast period of 2023-2030.

The key regions considered for the Global Lung Cancer Diagnostics Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the high market penetration rates of technologically advanced products, the rising patient awareness, and the rising smoking prevalence level. According to the Centers for Disease Control and Prevention (CDC) in 2021, reported that nearly 12 of every 100 U.S. adults aged 18 years or older (11.5%) are cigarette smokers. This means an around 28.3 million adults in the United States currently smoke. Initiatives, such as smoking cessation programs conducted by the American Lung Association (ALA) and campaigns to increase awareness of the symptoms of lung cancer are expected to further boost the regional market growth. Asia Pacific is expected to grow significantly over the forecast period, driven by rising penetration of advanced lung cancer diagnostic tools and increasing awareness of disease symptoms.

Major market player included in this report are:
QIAGEN GmbH
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
Abbott Laboratories
Quest Diagnostics Incorporated
Biodesix Inc.
Amoy Diagnostics Co., Ltd.
Bio-Rad Laboratories, Inc.
Biocartis
Boditech Med Inc.

Recent Developments in the Market:
 In March 2023, Roche received approval from the U.S. FDA for VENTANA PD-L1 (SP263) Assay, to identify non-small cell lung cancer (NSCLC) patients for Libtayo treatment.
 In March 2023, Agilent Technologies Inc. acquired Resolution Bioscience Inc. to expand the NGS-based cancer treatment capabilities. This acquisition is aimed to strengthen Agilent's position in the market.
 In October 2022, Quest Diagnostics announced a new partnership with Decode Health. This has helped the company in decreasing the time and expense involved in creating fresh diagnostic tests and finding new medication targets for various cancers.
 In August 2022, F. Hoffmann-La Roche Ltd. launched a Digital LightCycler System, a next-generation digital PCR system designed for laboratories performing highly sensitive and precise DNA and RNA analysis in oncology and infectious diseases.

Global Lung Cancer Diagnostics Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered – Cancer Type, Test, End User, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:


By Cancer Type:
Small Cell Lung Cancer
Non-small Cell Lung Cancer

By Test:
Imaging Test
Biopsy
Sputum Cytology
Molecular Testing

By End User:
Hospitals
Specialty Clinics
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
QIAGEN GmbH
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
Abbott Laboratories
Quest Diagnostics Incorporated
Biodesix Inc.
Amoy Diagnostics Co., Ltd.
Bio-Rad Laboratories, Inc.
Biocartis
Boditech Med Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.